Stock SRZN SURROZEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Surrozen, Inc. Share Price

Equities

SRZN

US86889P2083

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 02:00:00 27/04/2024 am IST 		5-day change 1st Jan Change
8.98 USD +4.30% Intraday chart for Surrozen, Inc. -4.52% -4.47%
10/04 Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
08/04 Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing MT

Financials

Sales 2024 * - Sales 2025 * - Capitalization 28.72M 2.4B
Net income 2024 * -27M -2.25B Net income 2025 * -43M -3.59B EV / Sales 2024 * -
Net cash position 2024 * 19.3M 1.61B Net cash position 2025 * 85M 7.09B EV / Sales 2025 * -
P/E ratio 2024 *
-1.23 x
P/E ratio 2025 *
-1.64 x
Employees 42
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.34%
More Fundamentals * Assessed data

Chart Surrozen, Inc.

Dynamic Chart

Latest news about Surrozen, Inc.

Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing MT
Surrozen, Inc. announced that it has received $17.500008 million in funding from The Column Group, LLC, Ra Capital Management, Inc. CI
Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis CI
Surrozen, Inc. announced that it expects to receive $17.549999 million in funding CI
Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer CI
Sector Update: Health Care Stocks Softer Late Thursday Afternoon MT
Sector Update: Health Care Stocks Weaker Thursday Afternoon MT
Surrozen to Stop Inflammatory Bowel Disease Clinical Trial; Shares Fall MT
Surrozen, Inc. Provides Corporate Update on Clinical Programs CI
Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis CI
Surrozen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Surrozen, Inc. Announces Management Changes CI
Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell Microcap Index CI
More news

Analyst Recommendations on Surrozen, Inc.

Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing MT
JPMorgan Downgrades Surrozen to Underweight From Neutral MT
BofA Securities Downgrades Surrozen to Underperform From Neutral, Adjusts Price Target to $1 From $5 MT
JPMorgan Initiates Surrozen at Neutral MT
BofA Securities Downgrades Surrozen to Neutral From Buy, Sets Price Target at $5 MT
More recommendations

Press releases Surrozen, Inc.

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis AQ
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043 AQ
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules AQ
Surrozen Provides Corporate Update on Clinical Programs AQ
Surrozen Provides Third Quarter 2023 Financial Results AQ
More press releases

Quotes and Performance

1 day+4.30%
1 week-4.52%
Current month-42.84%
1 month-34.21%
3 months+18.16%
6 months+33.04%
Current year-4.47%
More quotes

Highs and lows

1 week
8.14
Extreme 8.14
9.84
1 month
8.14
Extreme 8.14
16.19
Current year
7.15
Extreme 7.15
16.19
1 year
4.50
Extreme 4.5
16.19
3 years
4.50
Extreme 4.5
210.00
5 years
4.50
Extreme 4.5
210.00
10 years
4.50
Extreme 4.5
210.00
More quotes

Managers and Directors - Surrozen, Inc.

Managers TitleAgeSince
Craig Parker CEO
 Chief Executive Officer 63 01/18/01
Charles Williams DFI
 Director of Finance/CFO 46 01/20/01
Members of the board TitleAgeSince
Craig Parker CEO
 Chief Executive Officer 63 01/18/01
Eric Bjerkholt BRD
 Director/Board Member 64 05/23/05
Mace Rothenberg BRD
 Director/Board Member 67 01/21/01
More insiders

Quotes

Date Price Change Volume
26/24/26 8.98 +4.30% 11,126
25/24/25 8.61 -4.01% 5,086
24/24/24 8.97 -0.44% 8,980
23/24/23 9.01 -2.59% 2,309
22/24/22 9.25 -1.65% 9,310

Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST

More quotes

Company Profile

Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company's lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins, which are involved in activation and enhancement of the Wnt pathway. Its two technologies, Surrozen Wnt signal Activating Protein (SWAP) and Surrozen Wnt signal Enhancers Engineered for Tissue Specificity (SWEETS), enable it to potently and selectively modulate Wnt signaling through the generation of Wnt and R-spondin mimetics. SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. SWEETS molecules are designed to amplify the body’s response to naturally occurring Wnt proteins. Its product candidates include SZN-1326, SZN-043 and SZN-413.
Sector
Biotechnology & Medical Research
Calendar
08/05/2024 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
8.98 USD
Average target price
33 USD
Spread / Average Target
+267.49%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SURROZEN, INC. Stock Surrozen, Inc.
-4.47% 28.72M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SRZN Stock